MYO MYOMO, INC.
FY2025 10-K
MYOMO, INC. (MYO) filed its fiscal year 2025 10-K annual report with the SEC on Mar 9, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Wearable myoelectric-controlled upper limb orthoses for neuromuscular disorders and paralysis
- • New emphasis on upcoming MyoPro3 and MyoPal pediatric device to expand product lineup
Management Discussion & Analysis
- • Revenue $40.9M in 2025, up 26% YoY from $32.6M driven by higher volume and ASP; direct billing $30.4M (74% of total, +20%), International $6.8M (+48%), U.S. O&P $2.9M (doubled), VA $0.8M (-31%)
- • Gross margin declined to 65.7% in 2025 from 71.2% in 2024, due to higher overhead capitalization changes and warranty expenses
Risk Factors
- • CMS reclassification of MyoPro to brace benefit category effective January 1, 2024 enabling lump sum reimbursement around $34,970 to $68,800 per device
- • Medicare Advantage plans reduced MyoPro authorizations causing 2% revenue decline in 2025; 20% of product revenues from these plans in 2025
Financial SummaryXBRL
Revenue
$41M
Net Income
-$16M
Gross Margin
65.7%
Operating Margin
-35.2%
Net Margin
-38.1%
ROE
-136.6%
Total Assets
$39M
EPS (Diluted)
$-0.37
Operating Cash Flow
-$15M
Source: XBRL data from MYOMO, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on MYOMO, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.